Why 2017 Was a Year to Forget for Pfizer Inc.
The S&P 500 index soared 19% in 2017 (so far). The healthcare sector performed even better, with year-to-date gains of close to 21%. Several major drugmakers completed significant acquisitions. Some biopharmaceutical companies enjoyed tremendous revenue and earnings gains this year. But for Pfizer (NYSE: PFE), none of this was applicable.
Although 2017 wasn't a horrible year for Pfizer, with the stock gaining more than 11%, it wasn't exactly a great one, either. Here are three key reasons why this was a year to forget for the big pharma company.
Image source: Getty Images.
Source: Fool.com
Pfizer Inc. Stock
€25.37
-1.190%
With 31 Buy predictions and 4 Sell predictions Pfizer Inc. is one of the favorites of our community.
With a target price of 41 € there is a hugely positive potential of 61.61% for Pfizer Inc. compared to the current price of 25.37 €.
